These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1827708)

  • 41. Complementary DNA libraries and neurological disease.
    Joseph B; Furneaux H
    Arch Neurol; 1998 Jun; 55(6):785-8. PubMed ID: 9626768
    [No Abstract]   [Full Text] [Related]  

  • 42. Huntington's disease: genetically programmed cell death in the human central nervous system.
    Martin JB
    Nature; 1982 Sep; 299(5880):205-6. PubMed ID: 6213865
    [No Abstract]   [Full Text] [Related]  

  • 43. [Present status of neurology in 1979].
    Autret A
    Rev Prat; 1979 Jun; 29(35):2751-68. PubMed ID: 158824
    [No Abstract]   [Full Text] [Related]  

  • 44. Pathobiology of neuronal storage disease.
    Walkley SU
    Int Rev Neurobiol; 1988; 29():191-244. PubMed ID: 3042663
    [No Abstract]   [Full Text] [Related]  

  • 45. Genomics and degenerative diseases of the nervous system.
    Martin JB
    J Law Med Ethics; 2000; 28(4 Suppl):30-8. PubMed ID: 11244842
    [No Abstract]   [Full Text] [Related]  

  • 46. From spontaneous to induced neurological mutations: a personal witness of the ascent of the mouse model.
    Rakic P
    Results Probl Cell Differ; 2000; 30():1-19. PubMed ID: 10857183
    [No Abstract]   [Full Text] [Related]  

  • 47. Re-thinking the brain: a frog leaps.
    Bax MC
    Dev Med Child Neurol; 2002 Nov; 44(11):723. PubMed ID: 12418610
    [No Abstract]   [Full Text] [Related]  

  • 48. Autophagy in neurological diseases: An update.
    Chu CT
    Neurobiol Dis; 2019 Feb; 122():1-2. PubMed ID: 30342093
    [No Abstract]   [Full Text] [Related]  

  • 49. [Systematic nervous disorders and hereditary problems].
    VAN BOGAERT L
    Paris Med; 1947 Dec; 37(52):II. PubMed ID: 18909778
    [No Abstract]   [Full Text] [Related]  

  • 50. Synchrotron infrared microspectroscopy detecting the evolution of Huntington's disease neuropathology and suggesting unique correlates of dysfunction in white versus gray brain matter.
    Bonda M; Perrin V; Vileno B; Runne H; Kretlow A; Forró L; Luthi-Carter R; Miller LM; Jeney S
    Anal Chem; 2011 Oct; 83(20):7712-20. PubMed ID: 21888376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Electroconvulsive shock ameliorates disease processes and extends survival in huntingtin mutant mice.
    Mughal MR; Baharani A; Chigurupati S; Son TG; Chen E; Yang P; Okun E; Arumugam T; Chan SL; Mattson MP
    Hum Mol Genet; 2011 Feb; 20(4):659-69. PubMed ID: 21106706
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The cytoprotective effects of dantrolene: a ryanodine receptor antagonist.
    Inan S; Wei H
    Anesth Analg; 2010 Dec; 111(6):1400-10. PubMed ID: 20861418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration.
    Yamamoto A; Simonsen A
    Neurobiol Dis; 2011 Jul; 43(1):17-28. PubMed ID: 20732422
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease.
    Zabel C; Mao L; Woodman B; Rohe M; Wacker MA; Kläre Y; Koppelstätter A; Nebrich G; Klein O; Grams S; Strand A; Luthi-Carter R; Hartl D; Klose J; Bates GP
    Mol Cell Proteomics; 2009 Apr; 8(4):720-34. PubMed ID: 19043139
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Factors associated with HD CAG repeat instability in Huntington disease.
    Wheeler VC; Persichetti F; McNeil SM; Mysore JS; Mysore SS; MacDonald ME; Myers RH; Gusella JF; Wexler NS;
    J Med Genet; 2007 Nov; 44(11):695-701. PubMed ID: 17660463
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transcriptional signatures in Huntington's disease.
    Cha JH
    Prog Neurobiol; 2007 Nov; 83(4):228-48. PubMed ID: 17467140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.
    Leegwater-Kim J; Cha JH
    NeuroRx; 2004 Jan; 1(1):128-38. PubMed ID: 15717013
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression of normal and mutant huntingtin in the developing brain.
    Bhide PG; Day M; Sapp E; Schwarz C; Sheth A; Kim J; Young AB; Penney J; Golden J; Aronin N; DiFiglia M
    J Neurosci; 1996 Sep; 16(17):5523-35. PubMed ID: 8757264
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine.
    Mayeux R; Schupf N
    Am J Public Health; 1995 Sep; 85(9):1280-4. PubMed ID: 7661240
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopamine receptor genes: new tools for molecular psychiatry.
    Niznik HB; Van Tol HH
    J Psychiatry Neurosci; 1992 Oct; 17(4):158-80. PubMed ID: 1450188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.